Association of Advanced Glycation End Products With Lower-Extremity Atherosclerotic Disease in Type 2 Diabetes Mellitus
Lingwen Ying,Yun Shen,Yang Zhang,Yikun Wang,Yong Liu,Jun Yin,Yufei Wang,Jingrong Yin,Wei Zhu,Yuqian Bao,Jian Zhou
DOI: https://doi.org/10.3389/fcvm.2021.696156
IF: 3.6
2021-09-10
Frontiers in Cardiovascular Medicine
Abstract:Aims: Advanced glycation end products (AGEs) were reported to be correlated with the development of diabetes, as well as diabetic vascular complications. Therefore, this study aimed at investigating the association between AGEs and lower-extremity atherosclerotic disease (LEAD). Methods: A total of 1,013 type 2 diabetes patients were enrolled. LEAD was measured through color Doppler ultrasonography. The non-invasive skin autofluorescence method was performed for AGEs measurement. Considering that age plays an important role in both AGEs and LEAD, age-combined AGEs, i.e., AGE age index (define as AGEs × age/100) was used for related analysis. Results: The overall prevalence of LEAD was 48.9% (495/1,013). Patients with LEAD showed a significantly higher AGE age ( p < 0.001), and the prevalence of LEAD increased with ascending AGE age levels ( p for trend < 0.001). Logistic regression analysis revealed that AGE age was significantly positively associated with risk of LEAD, and the odds ratios of presence of LEAD across quartiles of AGE age were 1.00, 1.72 [95% confidence interval (CI) = 1.14–2.61], 2.72 (95% CI = 1.76–4.22), 4.29 (95% CI = 2.69–6.85) for multivariable-adjusted model (both p for trend < 0.001), respectively. The results were similar among patients of different sexes, body mass index, and with or without diabetes family history. Further, AGE age presented a better predictive value for LEAD than glycated hemoglobin A 1c (HbA 1c ), with its sensitivity, specificity, and area under the curve of 75.5% (95% CI = 71.6–79.2%), 59.3% (95% CI = 54.9–63.6%), and 0.731 (0.703–0.758), respectively. Conclusion: AGE age , the non-invasive measured skin AGEs combined with age, seems to be a more promising approach than HbA 1c in identifying patient at high risk of LEAD.
cardiac & cardiovascular systems